CX3CR1 and neoplasm: According to Yamauchi et al. [18], the administration of immune checkpoint inhibitor immunotherapies to tumor-bearing mice has increased both T-cell receptor frequency and clonality within the peripheral CX3CR1+CD8+ T-cell subset.